Evolving Approaches to ALL Treatment: CAR T-cell Therapy | Supplements And Featured Publications

The Evolving Approaches to ALL Treatment: CAR T-cell Therapy publication covers some of the latest practice-changing advances as it relates to emerging therapeutic strategies for patients with acute lymphoblastic leukemia.

Obe-cel May Mark Additional Treatment Option for R/R B-ALL

March 21, 2022

Article

Efforts are underway to evaluate novel, durable treatment options for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia in the phase 1b/2 FELIX trial evaluating obecabtagene autoleucel, a novel, second-generation CAR T-cell therapy.

Dr. Park on the Dosing Strategies Utilized in the FELIX Trial in R/R ALL

March 10, 2022

Video

Jae Park, MD, discusses dosing strategies utilized in the phase 1/2 FELIX trial in relapsed/refractory acute lymphoblastic leukemia.

Dr. Roddie on the Potential Utilization of Obe-Cel in R/R ALL

March 10, 2022

Video

Claire Roddie, MD, discusses the potential utilization of obecabtagene autoleucel in relapsed/refractory acute lymphoblastic leukemia.

Phase 1/2 FELIX Trial to Determine Obe-Cel Potential in Adult Patients With ALL

March 10, 2022

Article

Claire Roddie, MD, PhD, discusses how the phase 1/2 FELIX trial could impact the treatment landscape for acute lymphoblastic leukemia, how CAR T-cell therapies have evolved, and what challenges remain in making these treatments more accessible for patients.

Novel CAR T-cell Therapy Obe-cel Under Exploration in Relapsed/Refractory B-Cell ALL

February 15, 2022

Article

The safety and efficacy of the CD19-targeted CAR T-cell therapy obecabtagene autoleucel in the treatment of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia as part of the phase 1/2 FELIX trial.